Is Selank legal in the UK?

It is supplied as a material for laboratory research. It is not a licensed medicine here and cannot be prescribed or dispensed.

Does Russian registration mean Selank is proven?

It means one regulator assessed a submission against its own standards. Standards differ between agencies and have changed considerably over three decades.

Why will you not compare it to benzodiazepines on safety?

Describing a mechanistic difference is pharmacology. Claiming comparative safety against a licensed drug class is a therapeutic claim, and not one the published mechanism supports.

Selank (Tuftsin Analogue)

Selank Regulatory Status

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

Selank has a registration history in the Russian Federation. It holds no marketing authorisation from the MHRA, EMA or FDA, has not been through Western regulatory review, and is supplied in the UK for laboratory research only.

Key facts

Registered in: Russian Federation
MHRA status: Not authorised
EMA status: Not authorised
FDA status: Not approved
UK supply basis: Laboratory research only
Transferable?: No — authorisations are jurisdictional

What a national registration is

A marketing authorisation is one regulator's decision, about one product, in one jurisdiction, for defined indications, on the evidence submitted to it. It reflects that agency's evidentiary standards and its assessment of benefit and risk for its own population. It is not a statement about a compound in the abstract, and it does not travel.

Why it changes nothing in the UK

The MHRA assesses products submitted to it. A compound registered elsewhere has no UK status until a UK application is made and assessed, and Selank has not been through that process. Its position here is that of any unlicensed compound: not a medicine, not prescribable or dispensable, supplied for laboratory research.

Research material referenced

Selank 10mg — third-party HPLC tested

View — £24.99

The specific trap in this category

Selank's Russian registration is as an anxiolytic, and anxiety is exactly the kind of indication that invites a therapeutic claim. Reporting that a regulator registered a compound for a named indication is a statement about a decision. Saying or implying the compound treats that condition is a therapeutic claim about material supplied for research, and under the UK framework that is what converts a research supply into an unlicensed medicine. The MHRA opened investigations into UK retailers making precisely those claims in April 2026.

The benzodiazepine comparison, handled carefully

Selank's reported mechanism differs from that of benzodiazepines, and describing that difference is legitimate pharmacology. Translating it into a claim about comparative safety, dependence or withdrawal is not — that is a therapeutic comparison between a research compound and a licensed drug class, and the mechanism alone does not support it even before the regulatory question arises.

What would change the position

A UK marketing authorisation, following an application to and assessment by the MHRA. Nothing else does — not registration in another country, not published literature, not decades of use elsewhere.

Extended research context

The Selank (Tuftsin Analogue) deep dive

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue - and instructively, that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin - an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Research applications

▸Enkephalin and enkephalinase pathway research
▸GABAergic receptor expression studies in rodent models
▸BDNF expression research, including intranasal administration routes
▸Comparative work on proline-stabilised peptide design
▸Tuftsin and immunopeptide structure-activity research

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Do not rely on 280 nm absorbance — there are no aromatic residues
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Selank as an opioid or opioid agonist

Fix: Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

✗ Treating the benzodiazepine contrast as a safety claim

Fix: The mechanistic difference is real — expression-level rather than direct allosteric modulation — but it supports no comparative claim about safety or dependence.

✗ Citing tuftsin literature as evidence about Selank

Fix: Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is Selank legal in the UK?: It is supplied as a material for laboratory research. It is not a licensed medicine here and cannot be prescribed or dispensed.
Does Russian registration mean Selank is proven?: It means one regulator assessed a submission against its own standards. Standards differ between agencies and have changed considerably over three decades.
Why will you not compare it to benzodiazepines on safety?: Describing a mechanistic difference is pharmacology. Claiming comparative safety against a licensed drug class is a therapeutic claim, and not one the published mechanism supports.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Selank (Tuftsin Analogue) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum